QuantHealth Raises $45M to Let Pharm Test Clinical Trials with AI Before Spending Billions
Drug development is a gamble. More than 90% of drugs that enter clinical trials fail. Three out of four of those failures are because the drug didn’t work or wasn’t The post QuantHealth Raises $45M to Let Pharm Test Clinical Trials with AI Before Spending Billions appeared first on Ventureburn .
Israeli AI startup QuantHealth has raised $45 million in Series B funding, led by Qumra Capital, to revolutionize clinical trial design and reduce drug development risks. The round brings total funding to $75 million. Drug development is notoriously unpredictable, with over 90% of drugs failing at some stage, often leading to years and hundreds of millions in losses before failures are discovered.
QuantHealth aims to change this by simulating clinical trials before they are run, providing pharma companies with a faster, cheaper, and more efficient way to test trial designs and optimize protocols. The AI platform, developed by QuantHealth's CEO Orr Inbar and co-founder Arnon Horev, models different trial scenarios, identifies potential risks, and helps teams make informed decisions before committing capital.
The platform has already been used to simulate over 600 clinical trials across 30 medical indications with a predictive accuracy of up to 90%. Major pharmaceutical companies like Sanofi and others are already using QuantHealth to design trials and minimize risks. The new funding will be allocated towards improving the AI models and datasets, expanding the coverage to 40+ indications, integrating commercial planning into the platform, and hiring additional staff.
With this investment, QuantHealth believes it can reshape the drug development landscape, reduce failed late-stage trials, and accelerate the delivery of new therapies to patients.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
